MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research

MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology
Research

ST. JOSEPH, Mich., Sept. 2 /PRNewswire/ -- GeneGo, Inc., the leading
systems biology tools company, announced today that MD Anderson has become a
certified GeneGo Center of Excellence. MD Anderson researchers will have
institution-wide access to GeneGo's MetaCore data analysis suite, training and
advanced support. MD Anderson specializes in cancer treatment and research
and is well known for its advanced clinical trials programs. MetaCore will be
used throughout many research programs both as a central data repository,
management and collaboration platform for clinical OMICs data and as an
integrative pathway analysis suite.
Mary E. Edgerton, a pathologist performing cancer research at MD Anderson
and a long-term client, says "I have been using MetaCore for many years in my
research into pathways and networks that control aggressive behavior in
cancers. I am currently using it to infer networks from analysis of gene
expression array data for pathways in lung, brain, and breast cancer. I also
use the curated pathways to formulate mathematical models of molecular
networks that predict tumor behavior using multiscale modeling. Not only do I
find the product to be very useful, but I also appreciate the responsiveness
of the staff at GeneGo to my technical questions and suggestions. "
"MD Anderson is renowned for their pioneering work in oncology. I have
known some of the MD's there for a while and I admire their dedication to
their patients and to working hard to find cures," said Julie Bryant, GeneGo's
VP of Business development. "We are proud to have them as an institution
customer and a Center of Excellence. We have a large development program in
the area of cancer system biology tools supported by NCI and we are glad to
see this work appreciated by some of the best oncology professionals in the
world working at MD Anderson."
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based
pathway analysis, cheminformatics & bioinformatics software for life science
research. The original computational MetaDiscovery(TM) platform allows an
integration and expert analysis of different kinds of experimental data (mRNA
expression, proteomics, metabolomics, microRNA assays and other phenotypic
data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics)
within the framework of curated biological pathways and networks. GeneGo's
flagship product, MetaCore 5.0(TM), assists pharmaceutical scientists in the
areas of target selection and validation, data mining in biology,
identification of biomarkers for disease states and toxicology. The second
product, MetaDrug 5.0(TM) is designed for prediction of human metabolism,
toxicity and biological effects for novel small molecules compounds.
MetaBase(TM) represents the knowledge base for MetaCore.
For more information, please visit the company's web site at
http://www.genego.com.
SOURCE GeneGo, Inc.

Julie Bryant, VP Business Development and Marketing of GeneGo, Inc.,
+1-858-756-7996, julie@genego.com